Articles From: FDA Approves Expansion of Pivotal Scleroderma STAR Trial to 20 Clinical Sites to Fed's response to HSBC to be 'closely watched,' senator says


2015/2/26
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it received approval from FDA to expand the number of Scleroderma clinical trial sites from 12 to 20 centers in the United States.
Sign-up for FDA Approves Expansion of Pivotal Scleroderma STAR Trial to 20 Clinical Sites investment picks
2014/12/16
Cerus Corporation (NASDAQ: CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for plasma.
Sign-up for FDA Approves INTERCEPT Blood System for Plasma investment picks
2014/12/4
Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi ® (ruxolitinib) for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Sign-up for FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera investment picks
2014/12/23
Teva Pharmaceutical Industries Ltd.
Sign-up for FDA Approves Teva’s GRANIX® (tbo-filgrastim) Injection for Self-Administration investment picks
2014/12/15
SALT LAKE CITY, Dec.
Sign-up for FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021 investment picks
2015/2/18
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID ® (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). REVLIMID plus dexamethasone was previously approved in June 2006 for use in multiple myeloma patients who have received at least one prior therapy.
Sign-up for FDA Expands Indication for REVLIMID® (Lenalidomide) in Combination with Dexamethasone to Include Patients Newly Diagnosed with Multiple Myeloma investment picks
2015/3/2
SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Atara's optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD), a type of malignancy occurring after allogeneic hematopoietic cell transplantation (HCT). Allogeneic HCT is also commonly called a bone marrow transplant.
Sign-up for FDA Grants Breakthrough Therapy Designation to Epstein-Barr Virus (EBV) Targeted T-Cells for Treatment of EBV-Associated Lymphoproliferative Disease investment picks
2015/2/2
bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LentiGlobin ® BB305 Drug Product for the treatment of transfusion-dependent patients with beta-thalassemia major.
Sign-up for FDA Grants Breakthrough Therapy Designation to LentiGlobin for Treatment of Beta-Thalassemia Major investment picks
2014/12/10
Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced that the U.S. Food and Drug Administration (FDA) has granted conditional approval for an Investigational Device Exemption (IDE) for a pivotal clinical trial, named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 patients in the United States.
Sign-up for FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma investment picks
2015/1/26
RESEARCH TRIANGLE PARK, N.C., Jan.
Sign-up for FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema investment picks
2015/1/29
REDWOOD CITY, Calif., Jan.
Sign-up for FDA Grants Orphan Drug Designations to OncoMed's Tarextumab for the Treatment of Pancreatic and Small Cell Lung Cancer investment picks
2015/3/2
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company’s Biologics License Application (BLA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for treatment of patients with infantile- and juvenile-onset hypophosphatasia (HPP). The BLA submission is supported by data from 71 treated patients with HPP enrolled in three prospective studies and their extensions, as well as two retrospective natural history studies.
Sign-up for FDA Grants Priority Review for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia investment picks
2015/1/29
CorMedix is Developing Neutrolin for the Prevention of Catheter Related Bloodstream Infections and Maintenance of Catheter Patency in Hemodialysis, Oncology and Intensive Care BRIDGEWATER, N.J. , Jan.
Sign-up for FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.'s Lead Product Candidate in the U.S. investment picks
2015/2/23
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today confirmed that the U.S. Food and Drug Administration (FDA) has granted seven years of market exclusivity in the U.S. to Ryanodex ® (dantrolene sodium) for Injectable Suspension for the treatment of malignant hyperthermia (MH). Ryanodex was designated an orphan drug in August 2013 and was approved by the FDA in July 2014 for this indication.
Sign-up for FDA Grants Seven Years’ Market Exclusivity to Eagle Pharmaceuticals’ Ryanodex for the Treatment of Malignant Hyperthermia investment picks
2015/1/7
PRINCETON, N.J. , Jan.
Sign-up for FDA Grants Soligenix "Fast Track" Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma investment picks
2015/1/7
Generic biotech drugs took one step close to reality after a Food and Drug Administration advisory panel recommended the agency approve a Novartis AG (NVS) version of Amgen's Inc.'s (AMGN) drug Neupogen, according to media reports late Wednesday.
Sign-up for FDA panel recommends approval for first generic biotech drug investment picks
2015/3/3
By Thomas M.
Sign-up for FDA Warns on Drugs to Treat Low Testosterone Levels in Men investment picks
2015/3/3
By Thomas M.
Sign-up for FDA Warns on Low-Testosterone Drugs -- Update investment picks
2015/2/27
By Aaron Kuriloff The Federal Deposit Insurance Corp.
Sign-up for FDIC releases Doral Bank failure news early investment picks
2015/1/20
Edison International, the parent company of Southern California Edison (SCE), reminds high school seniors that there’s still time to apply for the 2014-15 Edison Scholars Program , which offers $1.2 million in scholarships to high school seniors planning to pursue college studies in science, technology, engineering or math ( STEM ) fields.
Sign-up for Feb. 1 is Deadline to Apply for $1.2 Million Edison Scholars Program investment picks
2015/2/13
http://www.marketwire.com/library/MwGo/2015/2/13/11G033210/eHealth,_Inc.-933475219778.gif MOUNTAIN VIEW, CA--(Marketwired - February 13, 2015) - Today eHealth, Inc. (NASDAQ: EHTH) ( eHealth.com ), the nation's first and largest private online health insurance exchange, released updated Price Index figures showing what last-minute health insurance shoppers are paying on average for health insurance.
Sign-up for February 15 Is the Last Day of Open Enrollment: As Deadline Approaches, Last-Minute Shoppers Are Paying an Average Premium of $273 per Month for Individual Health Insurance Coverage investment picks
2015/2/2
February Events! Town Hall with Heather Reisman, New Heather's Picks, & Indigo Spotlight Canada NewsWire FEBRUARY EVENTS AT INDIGO BOOKS & MUSIC TORONTO , Feb.
Sign-up for February Events! Town Hall with Heather Reisman, New Heather's Picks, & Indigo Spotlight investment picks
2015/3/3
By Greg Robb, MarketWatch WASHINGTON (MarketWatch) -- Federal Reserve Chairwoman Janet Yellen said Fed staff should "feel safe" to speak up about problems they uncover at the nation's biggest banks and not fear upsetting any relationship between the U.S. central bank and the industry.
Sign-up for Fed examiners free to flag problems at banks: Yellen investment picks
2014/12/18
By Ryan Tracy and Scptt Patterson WASHINGTON--Regulators on Thursday handed Wall Street banks a temporary reprieve they have been clamoring for from a rule that forces them to pull out of certain risky investments.
Sign-up for Fed gives banks more time to sell private-equity, hedge-fund stakes investment picks
2015/1/27
By Greg Robb, MarketWatch $22,000 per month for life in one retirement payment WASHINGTON (MarketWatch) -- Allan Landon, a former chief executive of Bank of Hawaii Corp., was tapped early this month for a seat on the Federal Reserve Board mainly to represent smaller community banks, which have felt left out in deliberations about post-financial-crisis regulations.
Sign-up for Fed nominee to represent smaller banks -- and the 1% investment picks
2014/12/9
The Federal Reserve is voting Tuesday on a proposal that would force systemically important banks to hold more capital than required under an international standard called Basel III.
Sign-up for Fed proposing big bank capital surcharges in excess of international standards investment picks
2015/1/20
By Pedro Nicolaci da Costa Widespread manipulation of key benchmark interest rates such as the London Interbank Offered Rate, or Libor, threatens public confidence in the financial system, and must be prevented through fines and criminal prosecution, Federal Reserve Gov.
Sign-up for Fed's Powell says rate rigging undermines trust in banking investment picks
2015/2/10
By Eric Garcia, MarketWatch WASHINGTON (MarketWatch) -- At a committee hearing on Tuesday, Sen.
Sign-up for Fed's response to HSBC to be 'closely watched,' senator says investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: FDA Approves Expansion of Pivotal Scleroderma STAR Trial to 20 Clinical Sites to Fed's response to HSBC to be 'closely watched,' senator says
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent